ApoA1 (Apolipoprotein A1) is synthesized in the liver and small intestine, and is the major protein component of high density lipoprotein (HDL) in the plasma. ApoA1 has a unique ability to capture and solubilize free cholesterol, and promotes cholesterol efflux from tissues to the liver for excretion. The process, called reverse cholesterol transport, is thought to inhibit atherogenesis. The recombinant human ApoA1 consists of 244 amino acids and predicts a molecular mass of 28.2 KD
